Yes, you can pursue legal action over dangerous medication side effects, but the lawsuit you file probably will not be a traditional class action. Most pharmaceutical injury cases are handled as mass torts or multidistrict litigation (MDL), where each plaintiff’s case is evaluated individually based on their specific injuries, medical costs, and damages. This distinction matters because it directly affects how much compensation you might receive. In a class action, everyone shares the same settlement equally.
In a mass tort, someone who suffered gastroparesis from a GLP-1 drug like Ozempic would receive a different payout than someone who experienced mild nausea — and that individual assessment often results in higher compensation for those with severe injuries. To have a viable case, you generally need to prove that a drug had a design defect, a manufacturing defect, or a marketing defect such as failure to warn about known risks. Right now, thousands of Americans are pursuing exactly these claims. The GLP-1 receptor agonist MDL alone has 3,191 pending claims for gastrointestinal injuries and another 37 for vision loss as of early 2026.
Table of Contents
- How Do Class Actions for Dangerous Medication Side Effects Actually Work?
- What You Must Prove to Win a Dangerous Drug Lawsuit
- Major Drug Lawsuits You Should Know About in 2026
- Steps to Take If You Believe a Medication Harmed You
- How FDA Recalls Factor Into Drug Injury Claims
- The Difference Between Settling and Going to Trial
- What to Expect Going Forward in Pharmaceutical Litigation
- Frequently Asked Questions
How Do Class Actions for Dangerous Medication Side Effects Actually Work?
The terminology gets thrown around loosely, but the legal mechanism behind most drug injury lawsuits is not a class action in the traditional sense. In a true class action, a court certifies a group of plaintiffs who all suffered essentially the same harm, and any settlement gets divided equally among them. That structure works well for consumer fraud cases — say, a company overcharged a million customers by the same dollar amount. But medication injuries are messy and personal. One patient on Suboxone might lose three teeth. Another might need full dental reconstruction. Treating those two cases identically would be absurd, which is why courts overwhelmingly funnel drug side effect claims into mass tort or MDL proceedings instead. In an MDL, cases from across the country get consolidated before a single federal judge for pretrial proceedings — discovery, expert testimony, motions to dismiss.
This prevents dozens of courts from duplicating the same work. But each plaintiff retains their own case. If the litigation doesn’t settle globally, individual cases go back to their home courts for trial. Only one person is technically needed to initiate the process, though there must be a good-faith basis for believing many others were similarly harmed. Once an MDL is established, attorneys advertise for additional plaintiffs, which is why you see so many TV and online ads asking whether you took a particular drug. The practical difference for you as a potential plaintiff is significant. In a mass tort, your compensation is tied to the severity of what happened to you — your medical bills, your lost wages, your pain and suffering. Settlement amounts in pharmaceutical cases can range from $350,000 to over $1 million for severe injuries, though outcomes vary widely based on the specifics of each case and the strength of the evidence linking the drug to the harm.
What You Must Prove to Win a Dangerous Drug Lawsuit
Filing a claim is one thing. Winning it requires proving that the drug was defective in one of three legally recognized ways. The first is a design defect — the drug’s formulation itself causes harm that the manufacturer knew about or should have known about through proper testing. The second is a manufacturing defect, where something went wrong during production: contamination, incorrect potency, failed dissolution testing, or labeling errors. Manufacturing quality issues account for 60 to 70 percent of all drug recalls, making this the most common type of defect identified by regulators. The third, and often the most contested in litigation, is a marketing defect or failure to warn — the manufacturer did not adequately disclose known risks to doctors and patients. However, proving a defect existed is only half the battle. you also need to establish causation, meaning you must show that the drug actually caused your specific injury and that your injury was not the result of an underlying condition, another medication, or some unrelated factor.
This is where pharmaceutical companies fight hardest. They will hire expert witnesses to argue that your gastroparesis was caused by diabetes itself rather than the GLP-1 drug you took, or that your dental problems preceded your use of Suboxone. If you cannot produce medical records showing a clear timeline — you were healthy before the drug, you took the drug, you developed the condition — your case weakens considerably. Statutes of limitations add another layer of urgency. These deadlines vary by state, and some allow only one year from the date you discovered (or should have discovered) the injury to file a claim. Miss that window and your case is dead regardless of its merits. Most attorneys who handle pharmaceutical litigation work on contingency, meaning no upfront fees and no payment unless you win, but that also means they are selective about which cases they take. If your evidence is thin or your injuries are minor, finding representation may be difficult.
Major Drug Lawsuits You Should Know About in 2026
The biggest pharmaceutical litigation right now involves GLP-1 receptor agonists — the blockbuster weight-loss and diabetes drugs including Ozempic, Wegovy, and Trulicity. As of February 2026, there are 3,191 pending claims in MDL 3094 alleging serious gastrointestinal injuries such as gastroparesis (stomach paralysis), ileus, and bowel obstruction. A separate MDL, number 3163, involves 37 claims for NAION, a form of sudden vision loss. Trials are currently scheduled for late 2026 or early 2027, which means settlement negotiations could intensify in the coming months. The FDA updated Ozempic’s label in February 2025 to add stronger warnings about severe pancreatitis and acute kidney injury from dehydration caused by the drug’s vomiting side effects. European regulators followed in June 2025 by adding NAION as a rare side effect to the label — lending additional weight to the vision loss claims.
Dupixent, a widely prescribed treatment for eczema and asthma, is facing a newer wave of lawsuits in 2026 alleging that the medication increases the risk of cutaneous T-cell lymphoma, a type of skin cancer. Reports of CTCL among Dupixent users were approximately 30 times higher compared to reports for all other medications, a striking disparity that plaintiff attorneys are building their cases around. Meanwhile, the Suboxone MDL has grown to nearly 2,000 claims consolidated in the Northern District of Ohio. Plaintiffs allege that Indivior, the manufacturer, failed to warn that the sublingual film formulation could cause severe tooth decay and dental destruction — injuries that many patients did not connect to the medication until years of damage had already occurred. These cases illustrate an important pattern: the drugs involved are not obscure. They are heavily marketed, widely prescribed, and in some cases culturally ubiquitous. If you have taken any of these medications and experienced the injuries described, the existing MDL infrastructure means there is already a legal pathway for your claim.
Steps to Take If You Believe a Medication Harmed You
The single most important thing you can do is preserve your medical records. Document the timeline meticulously: when you started the medication, what dosage you were on, when symptoms began, what diagnoses you received, and what treatments followed. Request copies of your pharmacy records showing the specific manufacturer and lot numbers of the drugs dispensed to you. If there was a recall involved, those lot numbers could be directly relevant. The United States has averaged 1,284 drug recalls per year since 2012, with a total of 15,749 recalls in that period, so the chances that a medication you took was subject to some form of recall action are not negligible. When choosing legal representation, you face a tradeoff. Large national firms that handle MDL cases have the resources and experience to go up against pharmaceutical companies, but you may receive less personal attention — your case becomes one of thousands in a portfolio.
Smaller firms may offer a more hands-on experience, but they might lack the financial resources to sustain years of litigation against a deep-pocketed defendant. Many attorneys work on contingency with no upfront cost to you, but fee structures vary. Some charge 33 percent of any settlement, others charge 40 percent, and some tack on additional costs for expenses. Ask about this before signing a retainer agreement. You should also verify that the attorney is actually filing in the relevant MDL rather than just collecting your information and referring your case to another firm for a referral fee. Do not wait to see whether a settlement is announced before consulting an attorney. Statutes of limitations continue to run regardless of whether litigation is ongoing, and some states have windows as short as one year. Even if a global settlement eventually materializes, you need to have filed or preserved your claim to participate in it.
How FDA Recalls Factor Into Drug Injury Claims
An FDA recall can strengthen your case, but it does not automatically entitle you to compensation. Recalls come in three classes. Class I recalls involve situations where the product could cause serious health consequences or death. Class II recalls mean the product may cause temporary or medically reversible adverse health consequences. Class III recalls involve products unlikely to cause adverse health consequences. The largest drug recall of 2025 involved prazosin hydrochloride, with approximately 580,844 bottles pulled from the market due to nitrosamine impurities above acceptable safety limits — contaminants linked to increased cancer risk. Here is the limitation that catches many people off guard: a recall means the FDA determined the product should not be on the market, but it does not establish that the product actually injured you specifically.
You still need to show individual causation. Conversely, the absence of a recall does not mean a drug is safe or that you have no case. Many of the current MDLs involve drugs that remain on the market with updated labels rather than recalled products. The GLP-1 drugs, for instance, are still prescribed to millions of patients. The lawsuits are not arguing that the drugs should not exist — they are arguing that patients were not adequately warned about serious risks, and that the manufacturers knew or should have known about those risks earlier than they disclosed them. If a drug you took was recalled, check the FDA’s recall database for the specific lot numbers involved and compare them to your pharmacy records. If there is a match, that is a strong piece of evidence. If there is no match, you may still have a case based on design or marketing defect theories, but you will need other evidence to support it.
The Difference Between Settling and Going to Trial
Most pharmaceutical MDLs resolve through settlement rather than trial, but the path to settlement is rarely straightforward. Typically, the court selects a handful of bellwether cases — representative cases that go to trial first to test the strength of both sides’ arguments. The outcomes of these bellwether trials heavily influence settlement negotiations. If plaintiffs win large verdicts, the manufacturer has strong incentive to settle the remaining cases.
If the manufacturer wins, plaintiffs may accept lower settlement offers or see their claims dismissed. The GLP-1 MDL has trials scheduled for late 2026 and early 2027, meaning we are still in the pre-bellwether phase. Historically, pharmaceutical MDLs can take anywhere from three to seven years from filing to resolution. The Suboxone litigation has been grinding through the courts since its consolidation, and while nearly 2,000 claims are pending, no global settlement has been announced. Patience is not optional in these cases — it is a requirement.
What to Expect Going Forward in Pharmaceutical Litigation
The next twelve to eighteen months will be pivotal for several major drug MDLs. The GLP-1 bellwether trials will set the tone for what could become one of the largest pharmaceutical settlements in recent history, given the sheer number of patients who have used Ozempic, Wegovy, and similar drugs. The Dupixent litigation is still in its early stages, and the strength of the CTCL signal — 30 times higher reporting rates — suggests this could expand significantly as more patients and attorneys become aware of the connection.
Pharmaceutical litigation tends to follow a cycle: a drug gains widespread adoption, adverse event reports accumulate, the FDA updates labels or issues recalls, lawsuits are filed, and eventually the legal system catches up. The average of nearly 1,300 drug recalls per year is not slowing down, and the growing sophistication of adverse event tracking means problems are being identified faster than in previous decades. If you believe you have been harmed by a medication, the legal infrastructure to pursue your claim likely already exists or is being built. The question is not whether you can file — it is whether you will do so before deadlines pass.
Frequently Asked Questions
What is the difference between a class action and a mass tort for drug injuries?
In a class action, all plaintiffs share the settlement equally regardless of individual harm. In a mass tort or MDL, each case is evaluated individually, and compensation is based on the severity of your specific injuries, medical costs, and damages. Drug cases almost always use the mass tort structure because injuries vary widely between patients.
How much does it cost to file a pharmaceutical lawsuit?
Most attorneys handle these cases on a contingency basis, meaning you pay nothing upfront and no fees unless you win. However, contingency fee percentages vary — typically between 33 and 40 percent of any recovery — and some firms charge additional costs for litigation expenses. Clarify the fee structure before signing any agreement.
How long do pharmaceutical lawsuits take to resolve?
These cases are rarely quick. From initial filing to resolution, pharmaceutical MDLs commonly take three to seven years. Bellwether trials must be conducted, settlement negotiations can stall, and appeals may extend timelines further. The GLP-1 litigation, for example, has trials scheduled for late 2026 and early 2027, with any global settlement likely coming after that.
Can I still file a claim if the drug was not recalled?
Yes. Many active MDLs involve drugs that remain on the market. The lawsuits typically focus on failure to warn — arguing that the manufacturer knew about risks but did not adequately disclose them. A recall strengthens a case but is not required to pursue one.
What is the statute of limitations for a drug injury lawsuit?
It varies by state and can be as short as one year from the date you discovered or should have discovered the injury. Some states apply a discovery rule, which starts the clock when you learn the drug caused your harm rather than when you first took it. Consult an attorney promptly to determine your deadline.
You Might Also Like
- Can You File a Paper Claim Instead of an Online Class Action Claim
- Can You File a Class Action Claim for a Service You Cancelled Years Ago
- Can You File a Class Action Claim Without a Social Security Number